Incruse Ellipta Aerosol, Powder
Product Images NDC 0173-0873

Product Visual Gallery

This gallery contains 19 technical images submitted to the FDA as part of the official labeling for Incruse Ellipta (NDC 0173-0873). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Glaxosmithkline Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Umeclidinium Chemical Structure (Incruse Ellipta Spl Graphic 01)

Chemical structure diagram of umeclidinium, the active ingredient in Incruse Ellipta. The diagram shows its molecular structure including aromatic rings, hydroxyl group, and a quaternary ammonium ion paired with a bromide ion.*

FDA Label Image

Figure 1. Impact Of Intrinsic And Extrinsic Factors On The Systemic Exposure Of Umeclidinium (Incruse Ellipta Spl Graphic 02)

A pharmacokinetic graph displaying the fold change and 90% confidence intervals for AUC and Cmax in populations including male gender, age over 65, severe renal impairment, moderate hepatic impairment, CYP2D6 poor metabolizers, and P-gp transport inhibition by verapamil. The chart shows recommendations of no dose adjustment for all groups with changes relative to reference values plotted along the horizontal axis.*

FDA Label Image

Figure 2. Adjusted Mean Change From Baseline In Postdose Serial Fev1 (ml) On Days 1 And 7, Day 1 (Incruse Ellipta Spl Graphic 03)

Line graph showing adjusted mean changes in FEV1 (mL) over time (hours) for different doses of umeclidinium compared to placebo. The graph includes data points for placebo, umeclidinium 15.6 mcg, 31.25 mcg, 62.5 mcg, and 125 mcg, illustrating their effects on FEV1 over a 6-hour period.*

FDA Label Image

Figure 2. Adjusted Mean Change From Baseline In Postdose Serial Fev1 (ml) On Days 1 And 7, Day 7 (Incruse Ellipta Spl Graphic 04)

A line graph showing adjusted mean changes in FEV1 (mL) over time (hours) for umeclidinium at doses of 15.6 mcg, 31.25 mcg, and 125 mcg compared to placebo. The graph illustrates pulmonary function response curves within a 24-hour period following administration.*

FDA Label Image

Figure 3. Least Squares (ls) Mean Change From Baseline In Fev1 (ml) Over Time (0-24 H) On Days 1 And 168 (trial 1 Subset Population), Day 1 (Incruse Ellipta Spl Graphic 05)

A line graph showing the least squares mean change from baseline in milliliters over time (in hours) for umeclidinium 62.5 mcg and placebo. The graph depicts two lines with different markers, indicating comparative changes across a 24-hour period.*

FDA Label Image

Figure 3. Least Squares (ls) Mean Change From Baseline In Fev1 (ml) Over Time (0-24 H) On Days 1 And 168 (trial 1 Subset Population), Day 168 (Incruse Ellipta Spl Graphic 06)

Line graph showing the least squares mean change from baseline in mL over 24 hours comparing umeclidinium 62.5 mcg to placebo. The x-axis represents time in hours, and the y-axis shows the mean change from baseline volume. Umeclidinium shows overall positive changes, while placebo shows negative or zero change over time.*

FDA Label Image

Parts Figure (Incruse Ellipta Spl Graphic 07)

An exploded illustration showing packaging components for Incruse Ellipta aerosol powder inhaler. The diagram includes the tray lid, inhaler device, desiccant pouch, tray containing the inhaler, carton box, and patient information leaflet.*

FDA Label Image

Ifu Figure A.jpg (Incruse Ellipta Spl Graphic 08)

An instructional illustration showing a hand peeling back the foil cover of a tray-like container. The arrow indicates the direction to remove the foil. This image likely demonstrates how to open the packaging of a medication or device component.*

FDA Label Image

Ifu Figure B (Incruse Ellipta Spl Graphic 09)

An instructional illustration showing three pills or tablets being discarded into an open trash can with the trash can lid placed beside it.*

FDA Label Image

Ifu Figure C.jpg (Incruse Ellipta Spl Graphic 10)

An instructional diagram of the Incruse Ellipta inhaler showing two labeled parts: the 'Cover' at the top and a 'Counter' display in the center, which indicates the number 30. The device is depicted with a textured grip area on the left side.*

FDA Label Image

Ifu Figure D.jpg (Incruse Ellipta Spl Graphic 11)

An illustration showing the Incruse Ellipta inhaler device with labeled parts: mouthpiece, counter, air vent, and cover. The diagram includes a hand demonstrating the inhaler cover being opened with a 'Click' sound indicated by an arrow.*

FDA Label Image

Ifu Figure E (Incruse Ellipta Spl Graphic 12)

An instructional illustration showing a person holding an inhaler device near their mouth. Arrows indicate the direction of inhalation from the device into the mouth.*

FDA Label Image

Ifu Figure F (Incruse Ellipta Spl Graphic 13)

An instructional line drawing showing a person using a handheld inhaler device by placing the mouthpiece in the mouth and pressing down on the base with fingers to release the medication. The image focuses on the proper hand positioning and inhaler use technique.*

FDA Label Image

Ifu Figure G.jpg (Incruse Ellipta Spl Graphic 14)

Illustration showing hands holding an inhaler device, demonstrating not to block the air vent with fingers as indicated by a 'no' symbol over the vent area. The image advises proper hand placement on the inhaler for correct use.*

FDA Label Image

Ifu Figure I.jpg (Incruse Ellipta Spl Graphic 15)

An instructional illustration showing a side view of a person's head and upper chest with text '3-4 seconds' and a clock face indicating the time. The image likely demonstrates the recommended breath holding duration after inhalation for the Incruse Ellipta aerosol powder.*

FDA Label Image

Ifu Figure I (Incruse Ellipta Spl Graphic 16)

Instructional illustration showing a person holding an inhaler device near their mouth, exhaling normally before inhaling the medication. The image emphasizes correct positioning and inhalation technique for using the inhaler.*

FDA Label Image

Ifu Figure J.jpg (Incruse Ellipta Spl Graphic 17)

An instructional diagram showing a partially opened Incruse Ellipta inhaler with an arrow indicating the opening direction of the mouthpiece cover. The inhaler has a dose counter displaying the number 29, illustrating how to prepare the device for use.*

FDA Label Image

Ifu Figure K.jpg (Incruse Ellipta Spl Graphic 18)

Illustration of the Incruse Ellipta inhaler device showing the mouthpiece cover open. The image highlights a red indicator window displaying the number 9, which likely indicates the remaining doses in the inhaler.*

FDA Label Image

Incruse Ellipta 30 Count Carton (Incruse Ellipta Spl Graphic 19)

Incruse Ellipta 62.5 mcg aerosol powder inhaler by GlaxoSmithKline LLC. The label shows umeclidinium inhalation powder for oral inhalation only. The package contains one Ellipta inhaler with a foil strip of 30 blisters. The front label includes dosing and ingredient details with the GSK logo.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.